Payment overview · 2025
General Payments
$23,795.53
135 reported records · 23 companies
Healthcare provider profile · identity verified
Jesse J Klein, DO
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · LARGO, FL · NPI 1982815288
Verified facts
What the public records show
CMS Open Payments records show Jesse J Klein, DO received $23,795.53 in general payments during 2025 across 135 reported records.
Abbott Laboratories accounted for 54.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $13,033.38 | 54.8% | 34 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$7,944.53 | 33.4% | 27 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $607.79 | 2.5% | 6 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $409.51 | 1.7% | 5 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $316.06 | 1.3% | 21 | 2025 |
| EBR SYSTEMS, INC. | Unresolved — no canonical attribution shown | $281.37 | 1.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $261.61 | 1.1% | 3 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $197.13 | 0.8% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $151.42 | 0.6% | 8 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $133.30 | 0.6% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $81.29 | 0.3% | 4 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $51.39 | 0.2% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $51.34 | 0.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.16 | 0.2% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $39.18 | 0.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.90 | 0.2% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $31.25 | 0.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.90 | 0.1% | 2 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $22.66 | 0.1% | 1 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $22.06 | 0.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.17 | 0.1% | 1 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $14.65 | 0.1% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $14.48 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $12,000.00 | 6 |
| Travel and Lodging | $7,109.47 | 6 |
| Food and Beverage | $4,686.06 | 123 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DIAMONDBACK CORONARY Normalized: diamondback coronary |
Device | Abbott Laboratories | $12,047.31 | 8 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $6,897.59 | 7 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc., Stryker Corporation | $1,001.85 | 10 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc., Stryker Corporation | $1,001.85 | 10 | 2025 |
Source payment records
|
|||||
| TRICLIP Normalized: triclip |
Device | Abbott Laboratories | $540.11 | 6 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $328.22 | 7 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $316.06 | 21 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $227.59 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $151.42 | 8 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $135.51 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN VBX Balloon Expandable Endo Normalized: gore viabahn vbx balloon expandable endo |
Device | W. L. Gore & Associates, Inc. | $130.02 | 1 | 2025 |
Source payment records
|
|||||
| TURBOHAWK Normalized: turbohawk |
Device | Medtronic, Inc. | $112.13 | 4 | 2025 |
Source payment records
|
|||||
| EMBLEM MRI S-ICD Normalized: emblem mri s icd |
Device | Boston Scientific Corporation | $97.73 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $57.86 | 3 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $51.34 | 2 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $45.88 | 7 | 2025 |
Source payment records
|
|||||
| PROTEGE RX Normalized: protege rx |
Device | Medtronic, Inc. | $43.94 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $39.18 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $36.90 | 2 | 2025 |
Source payment records
|
|||||
| EXCLUDER Conformable AAA Endoprosthesis with Active Control Normalized: excluder conformable aaa endoprosthesis with active control |
Device | W. L. Gore & Associates, Inc. | $34.45 | 1 | 2025 |
Source payment records
|
|||||
| SAVVYWIRE Normalized: savvywire |
Device | CARDIVA MEDICAL, INC. | $34.38 | 1 | 2025 |
Source payment records
|
|||||
| GORE EXCLUDER Iliac Branch Endoprosthesis Normalized: gore excluder iliac branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $32.66 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $31.25 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.90 | 2 | 2025 |
Source payment records
|
|||||
| General - Tachy Normalized: general tachy |
Device | Boston Scientific Corporation | $28.37 | 1 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROSTYLE Normalized: perclose prostyle |
Device | Abbott Laboratories | $26.45 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.43 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $22.66 | 1 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $22.06 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.63 | 1 | 2025 |
Source payment records
|
|||||
| Adempas Normalized: adempas |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK PERIPHERAL Normalized: diamondback peripheral |
Device | Abbott Laboratories | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| OPTOWIRE Normalized: optowire |
Device | CARDIVA MEDICAL, INC. | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| LIMFLOW SYSTEM Normalized: limflow system |
Device | Stryker Corporation | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX Normalized: epi sense guided coagulation system with visitrax |
Device | AtriCure, Inc. | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Cardiac Ambulatory Monitor Normalized: hillrom cardiac ambulatory monitor |
Device | Baxter Healthcare | $14.48 | 1 | 2025 |
Source payment records
|
|||||
| MITRACLIP Normalized: mitraclip |
Device | Abbott Laboratories | $13.90 | 1 | 2025 |
Source payment records
|
|||||
| XACT Normalized: xact |
Device | Abbott Laboratories | $11.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 129 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
43 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
129 | 46 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 262 | 112 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 208 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 200 | 89 |
| Atorvastatin Calcium | Atorvastatin Calcium | 162 | 72 |
| Clopidogrel | Clopidogrel Bisulfate | 154 | 77 |
| Losartan Potassium | Losartan Potassium | 148 | 61 |
| Eliquis | Apixaban | 129 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 32 |
| Lisinopril | Lisinopril | 85 | 45 |
| Potassium Chloride | Potassium Chloride | 78 | 31 |
| Carvedilol | Carvedilol | 75 | 35 |
| Furosemide | Furosemide | 74 | 33 |
| Xarelto | Rivaroxaban | 61 | 26 |
| Bumetanide | Bumetanide | 50 | 24 |
| Entresto | Sacubitril/Valsartan | 43 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 42 | 18 |
| Atenolol | Atenolol | 32 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | 17 |
| Sotalol | Sotalol Hcl | 29 | 15 |
| Nitroglycerin | Nitroglycerin | 28 | 19 |
| Farxiga | Dapagliflozin Propanediol | 27 | 11 |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | 11 |
| Ezetimibe | Ezetimibe | 26 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 23 | 13 |
| Dofetilide | Dofetilide | 19 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Repatha Syringe | Evolocumab | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $23,795.53 · 135 records | Abbott Laboratories | Adempas, Assure WCD, CARDIOMEMS, COREVALVE EVOLUT R, CT THROMBECTOMY SYSTEM KIT, DIAMONDBACK CORONARY, DIAMONDBACK PERIPHERAL, ELIQUIS, EMBLEM MRI S-ICD, EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX, ESPRIT, EXCLUDER Conformable AAA Endoprosthesis with Active Control, FLOWTRIEVER CATHETER, S, FUROSCIX, GORE EXCLUDER Iliac Branch Endoprosthesis, GORE VIABAHN VBX Balloon Expandable Endo, General - Tachy, General - Therapies, HAWKONE, Hillrom - Cardiac Ambulatory Monitor, JARDIANCE, Kerendia, LEQVIO, LIMFLOW SYSTEM, MITRACLIP, NEXLETOL, ONPATTRO, OPSUMIT, OPTOWIRE, Ozempic, PERCLOSE PROSTYLE, PROTEGE RX, REPATHA, SAVVYWIRE, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TRICLIP, TURBOHAWK, VYNDAQEL, Wegovy, XACT | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novartis Pharmaceuticals Corporation?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error